Research on Eco Animal Health Group PLC (EAH:LON) from Equity Development
Following the recent announcement of plans for commercialisation of ECOVAXXIN® MS, ECO Animal Health announces that the United States Department of Agriculture (USDA) has delivered a favourable safety assessment of ECOVAXXIN® MG, the Company’s live poultry vaccine targeting Mycoplasma gallisepticum. The USDA review and acceptance of ECOVAXXIN® MG safety data represents an important step towards securing marketing authorisation for the vaccine in the United States. EAH has estimated that ECOVAXXIN® MG has the potential to contribute peak revenue of c.£10.0m by 2036 as part of a portfolio of new products under development of which ECOVAXXIN® MG stands in the ‘late stage’, i.e. early contributor segment. The USDA safety approval acceptance adds further momentum to the path toward commercialisation for the vanguard of nine major products under development. Our fair value remains at 153p/share.